Literature DB >> 7648763

The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma.

R M Welch1, A Brown, J Ravitch, R Dahl.   

Abstract

OBJECTIVE: To assess the mechanism and rate of in vitro degradation of cisatracurium in aqueous buffer and in human and rat plasma.
METHODS: Cisatracurium was incubated in aqueous buffer at various pH values or in human and rat plasma maintained at pH 7.4 with HEPES buffer. Cisatracurium and the degradation products, laudanosine and the monoquaternary alcohol, were quantitated by HPLC with use of fluorescence detection.
RESULTS: In Sørenson's phosphate buffer, cisatracurium degraded spontaneously by a chemical process commonly referred to as "Hofmann elimination." The rate of degradation increased with increasing pH. From pH 6.4 to 7.8 there was a 6.5-fold increase in the rate of degradation of cisatracurium and, on a molar basis, the final decomposition product laudanosine accounted for all of the drug. At a pH of 7.4, cisatracurium degraded with a half-life of about 34.1 +/- 2.1 minutes. Cisatracurium incubated in human plasma degraded with a mean (+/- SD) half-life of 29.2 +/- 3.8 minutes, which is consistent with Hofmann elimination. Besides laudanosine, and unlike that observed in Sørenson's phosphate buffer, significant amounts of the monoquaternary alcohol were formed that slowly degraded to laudanosine. The micromoles of laudanosine formed eventually accounted for the total amount of cisatracurium incubated with human plasma. The monoquaternary alcohol appears to be a product of ester hydrolysis of a monoquaternary acrylate formed during the first step in Hofmann elimination. Evidence for esterase involvement at this step in the degradation of cisatracurium was based on inhibition studies with O-cresyl benzodioxaphosphorin oxide (CBDP), a specific carboxylesterase inhibitor. The addition of CBDP to human plasma completely blocked the formation of monoquaternary alcohol and converted the degradation of cisatracurium to total Hofmann elimination. In rat plasma cisatracurium was hydrolyzed, with a half-life of only 3 1/2 minutes, by carboxylesterases. The addition of CBDP increased the half-life to 25 minutes, which is consistent with Hofmann elimination.
CONCLUSION: In human plasma the rate-limiting step in the degradation of cisatracurium is Hofmann elimination, with the initial formation of a monoquaternary acrylate. The observation that the monoquaternary alcohol results from ester hydrolysis of the monoquaternary acrylate by plasma esterase(s) explains the presence of the monoquaternary alcohol metabolite in human plasma during clinical studies with cisatracurium. The rapid hydrolysis of cisatracurium by rat plasma relative to human indicates a major species difference in plasma esterase(s).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648763     DOI: 10.1016/0009-9236(95)90190-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 2.  [Esters and stereoisomers].

Authors:  V Nigrovic; C Diefenbach; H Mellinghoff
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 3.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium.

Authors:  V D Schmith; J Fiedler-Kelly; L Phillips; T H Grasela
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

5.  Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period.

Authors:  Jiayi Liu; Chunying Lu; Qirong Zou; Sheng Wang; Xuemei Peng
Journal:  Br J Clin Pharmacol       Date:  2016-10-16       Impact factor: 4.335

Review 6.  General anaesthesia: practical recommendations and recent advances.

Authors:  C Dodds
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

7.  Age and the neuromuscular blockading effects of cisatracurium.

Authors:  Jianrong Guo; Xiaofang Zhou; Xiaohong Yuan; Huachun Shen; Yiwei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 8.  Clinical pharmacokinetics of cisatracurium besilate.

Authors:  D F Kisor; V D Schmith
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 9.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats.

Authors:  Jessica M Jones; Michael D Raleigh; Paul R Pentel; Theresa M Harmon; Daniel E Keyler; Rory P Remmel; Angela K Birnbaum
Journal:  J Pharm Biomed Anal       Date:  2012-11-15       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.